RAMB - Setembro 2017

hen

732

ssoc

ras

2017; 63(9):729-732

A retrospective study conducted from multi-institu-

tional databases also evaluated the role of radiotherapy

techniques in patient survival, demonstrating the supe-

riority of IMRT or conformal techniques compared to

the conventional technique, with 5-year survival rates of

14% for IMRT or conformal radiotherapy compared with

11% for conventional radiotherapy (p=0.0001). Another

similar study demonstrated a better overall survival in the

comparison between the IMRT or conformal radiotherapy

techniques and the conventional technique, but did not

demonstrate superiority of IMRT over conformal radio-

therapy in terms of survival.

22,23

(B)

onclusion

Treatment with IMRT can provide more conformality and

protect more critical structures than conformal radio-

therapy, also allowing the dose escalation within the target,

without prolonging the treatment time. It is particularly

indicated for “superior sulcus” (Pancoast tumors), para-

vertebral and paracardiac tumors and in complex clinical

situations in which conformal radiotherapy does not enable

the release of non-toxic doses to organs at risk.

IMRT significantly reduces the risk of worsening

quality of life in lung cancer patients undergoing radia-

tion therapy.

There is less toxicity with the use of IMRT compared

with conformal radiotherapy for primary lung tumors,

particularly regarding the rates of grade ≥ 3 pneumonitis

and requiring feeding tube.

There is also longer survival with the use of IMRT or

conformal radiotherapy in relation to conventional ra-

diotherapy, but not with IMRT compared with conven-

tional radiotherapy.

onflict

interest

The authors declare no conflict of interest.

eferences

Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton

M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:

a phase 3 randomised controlled trial. Lancet. 2015; 385(9962):36-42.

2. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al.

Twice-daily compared with once-daily thoracic radiotherapy in limited small-

cell lung cancer treated concurrently with cisplatin and etoposide. N Engl

J Med. 1999; 340(4):265-71.

Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R, et al.;

PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-

small cell lung cancer. Cochrane Database Syst Rev. 2005; 10:CD002142.

Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, et al.

Induction chemoradiation and surgical resection for non-small cell lung

carcinomas of the superior sulcus: Initial results of Southwest Oncology

Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 2001;

121(3):472-83.

5. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al.

Meta-analysis of concomitant versus sequential radiochemotherapy in locally

advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(13):2181-90.

6. Almeida CE, Haddad CK, Ferrigno R. A evolução técnica da radioterapia

externa. In: Sociedade Brasileira de Radioterapia. Radioterapia Baseada em

Evidências. Recomendações da Sociedade Brasileira de Radioterapia. São

Paulo: SBRT. Cap. 2, p. 21-6.

Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et

al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC):

an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;

76(3 Suppl):S3-9.

Kong FM, Zhao J, Wang J, Finn CF. Radiation dose effect in locally advanced

non-small cell lung cancer. J Thorac Dis. 2014; 6(4):336-47.

Sundar JK, Mullapudi N, Yao H, Spivack SD, Rahman I. Lung cancer and

its association with chronic obstructive pulmonary disease: update on nexus

of epigenetics. Curr Opin Pulm Med. 2011; 17(4):279-85.

10.

Liu HH, Wang X, Dong L, Wu Q, Liao Z, Stevens CW, et al. Feasibility of

sparing lung and other thoracic structures with intensity-modulated

radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys.

2004; 58(4):1278-79.

11.

Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, et al. Comparison

of 2 common radiation therapy techniques for definitive treatment of small

cell lung cancer. Int J Radiat Oncol Biol Phys. 2013; 87(1):139-47.

12.

Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith B. Intensity

modulated radiotherapy for stage III non-small cell lung cancer in the United

States: predictors of use and association with toxicities. Lung Cancer. 2013;

82(2):252-9.

13. Chang JY. Intensity-modulated radiotherapy, not 3 dimensional conformal,

is the preferred technique for treating locally advanced lung cancer. Semin

Radiat Oncol. 2015; 25(2):110-6.

14. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, et al. Initial evaluation

of treatment-related pneumonitis in advanced-stage non-small-cell lung

cancer patients treated with concurrent chemotherapy and intensity-

modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 68(1):94-102.

15.

Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, et al.

Influence of technologic advances on outcomes in patients with unresectable

locally advanced non-small-cell lung cancer receiving concomitant

chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010; 76(3):775-81.

16. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al.

Clinical dose-volume histogram analysis for pneumonitis after 3D treatment

for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;

45(2):323-9.

17.

Hope AJ, Lindsay PE, El Naqa I, Alaly JR, Vicic M, Bradley JD, et al. Modeling

radiation pneumonitis risk with clinical, dosimetric, and spatial parameters.

Int J Radiat Oncol Biol Phys. 2006; 65(1):112-24.

18.

Rodrigues G, Lock M, D’Souza D, Yu E, Van Dyk J. Prediction of radiation

pneumonitis by dose-volume histogram parameters in lung cancer – a

systematic review. Radiother Oncol. 2004; 71(2):127-38.

19.

Bradley J, GrahamMV, Winter K, Purdy JA, Komaki R, Roa WH, et al. Toxicity

and outcome results of RTOG 9311: a phase I-II dose-escalation study using

three-dimensional conformal radiotherapy in patients with inoperable non-

small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005; 61(2):318-28.

20.

Rose J, Rodrigues G, Yaremko B, Lock M, D’Souza D. Systematic review of

dose-volume parameters in the prediction of esophagitis in thoracic

radiotherapy. Radiother Oncol. 2009; 91(3):282-7.

21.

Movsas B, Hu C, Sloan J, Bradley J, Kavadi VS, Narayan S, et al. Quality of

Life (QOL) analysis of the Randomized Radiation (RT) dose-escalation

NSCLC Trial (RTOG 0617): the rest of the story. Int J Radiat Oncol Biol

Phys. 2013; 87(2):suppl, S1-2.

22.

Sher DJ, Koshy M, Liptay MJ, Fidler MJ. Influence of conformal radiotherapy

technique on survival after chemoradiotherapy for patients with stage III

non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014;

120(13):2060-8.

23.

Harris JP, Murphy JD, Hanlon AL, Le QT, Loo BW Jr, Diehn M. A population-

based comparative effectiveness study of radiation therapy techniques in

stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;

88(4):872-84.

24. Ayadi M, Zahra N, Thariat J, Bouilhol G, Boissard P, Van Houtte P, Claude

L, Mornex F. Radiothérapie conformationelle avec modulation d’intensité

dans les carcinomes bronchiques non à petites cellules. Cancer Radiotherapie.

2014; 18(5-6):406-13.